Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

SA Transcripts158.86K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Humacyte, Inc. (HUMA) TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM EST Company Participants Laura Niklason - Founder, President, CEO & Director Conference Call Participants Joshua Jennings - TD Cowen, Research Division Presentation Joshua JenningsTD Cowen, Research Division Good morning. We're getting towards the end of the morning, but -- or actually middle of the morning, sorry. I'm Josh Jennings from the TD Cowen Medical Research Medical Devices Research team, and we are excited to have executives from Humacyte in our midst, in our presence, multiyear participant. Thank you guys for supporting the conference and especially this year, it's the -- we have CEO, President and Founder, Dr. Laura Niklason; and CFO, Dale Sanders, is here as well. But I'm going to hand it over to Laura to run through the Humacyte story and get us up to speed on an exciting regenerative medicine technology. Laura, thanks so much for coming again this year. Laura NiklasonFounder, President, CEO & Director Thank you, Josh. Really appreciate the opportunity. I know this is a 30-minute slot. I'm going to try to keep this to 20 or 25 minutes in case there are questions. But there's a lot of really exciting stuff that has happened in the last year and that's upcoming in the next year. I'm really excited to talk about that. So for those who are not familiar with the Humacyte story, this is an engineered tissue platform where we use normal human cells to create functional implantable human tissues at commercial scale. The way that we grow these tissues allows us to produce them so that when they're implanted into a patient, even though they come from a cell bank, they do not require any immunosuppression. In fact, we've treated more than 700 patients during clinical and commercial phases